WO2008002382B1 - Compositions and methods for enhancing brain function - Google Patents

Compositions and methods for enhancing brain function

Info

Publication number
WO2008002382B1
WO2008002382B1 PCT/US2007/013376 US2007013376W WO2008002382B1 WO 2008002382 B1 WO2008002382 B1 WO 2008002382B1 US 2007013376 W US2007013376 W US 2007013376W WO 2008002382 B1 WO2008002382 B1 WO 2008002382B1
Authority
WO
WIPO (PCT)
Prior art keywords
supplement
vinpocetine
acetyl
nutritional supplement
dosage unit
Prior art date
Application number
PCT/US2007/013376
Other languages
French (fr)
Other versions
WO2008002382A1 (en
Inventor
Josh Reynolds
Original Assignee
Josh Reynolds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Josh Reynolds filed Critical Josh Reynolds
Publication of WO2008002382A1 publication Critical patent/WO2008002382A1/en
Publication of WO2008002382B1 publication Critical patent/WO2008002382B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieve the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine, and acetyl-L-carnitine at typically less than 1600 mg per daily dosage.

Claims

AMENDED CLAIMS received by the International Bureau on 18 January 2008 (18.01.2008)
1. Λ nutritional supplement for enhancing at least one of short term working memory, memory consolidation and processing speed, mental clarity, mental energy, fluid intelligence, general reasoning and mood, comprising: hupcrzine A, vinpocetine, and acetyl-L-carnitine in a ratio of x : y : z, wherein x is between 0.8 and 1.2, y is between 80 and 12O, and 7, is between 8,000 and 12,000; and an optional additional ingredient, wherein the supplement is formulated for oral administration such that the huperrino A, vinpocetine, and acetyl-L-carnitine together account Cor at least 80 wt% of a dosage unit of the supplement.
2. The nutritional supplement of claim 1 wherein x is between 0.9 and 1.1 , y is between 90 and 110, and z is between 9,000 and 1 1 ,000,
3. The nutritional supplement of claim 1 wherein at least one of (a) huperzine A is present in the first component an amount of about 150 meg, (b) vinpocetine is present in the first component an amount of about 15 mg, and (e) acetyl-L-carnitine is present in the first component an amount of about 1,500 mg.
4. The nutritional supplement of claim 1 wherein lhe optional additional ingredient is folic acid in an amount of at least 1 mg per dosage unit or potassium in an amount of at least 100 mg per dosage unit.
5. The nutritional supplement of claim 1 wherein the supplement is formulated wilh an enteric coating.
6. The nutritional supplement of claim 1 wherein the additional ingredient is an inactive ingredient selected from the group consisting of a carrier, a binder, an cxcipicnt, and a dye.
7. The nutritional supplement of claim 1 wherein the huperzine A, vinpocetine, and acetyl-T .-carnitine together account for at least 90 wt% of a dosage unit of the supplement.
8. The nutritional supplement of claim 1 wherein the huperzine A, vinpocetine, and acetyl-L-carnitinc together account for at least 95 wt% of a dosage unit of the supplement.
9. The nutritional supplement of claim 1 wherein the dosage iinit of the supplement is equal or less than 1 ,600 mg.
10. The nutritional supplement of claim 1 further comprising an information stating that the nutritional supplement enhances at least, one of short term working memory, memory consolidation, memory processing speed, mental clarity, mental energy, fluid intelligence, general reasoning, and mood.
11. The nutritional supplement of claim 1 further comprising an interactive tool that allows at least one of validation of efficacy of the supplement and proper personal dosing, of the supplement.
12. A method of assisting enhancement of al least one of short term working memory, memory consolidation, and processing, speed, mental clarity, mental energy, fluid intelligence, general reasoning and mood in a person using a nutritional supplement, comprising: providing a composition that includes hupecrine A, vinpocetine, and acetyl-L- carnitinc in a ratio of x : y : z, wherein x is between 0.8 and 1.2, y is between 80 and 120, and z is between 8,000 and 12,000, and further providing an optional additional ingredient; formulating the supplement for oral administration such that the huperzinc A, vinpocetine, and acetyl-L-camitine together account for at least 80 wt% of a dosage unit of the supplement; and providing an information that the supplement in a clinical trial was effective to improve cognitive function.
13. The method of claim 12 wherein x is between 0.9 and 1.1 , y is between 90 and 110, and z is between 9,000 and 11,000.
14. The method of claim 12 wherein at least one of (a) huperzine A is present in the first component an amount of about 150 meg, (b) vinpocetine is present in the first component an amount of about 15 mg, and (c) acetyl-L-carnitine is present in the first component an amount of about 1,500 mg.
15. The method of claim 12 wherein the supplement is formulated with an enteric coating.
16. The method of claim 12 wherein the additional ingredient is an inactive ingredient selected from the group consisting of a carrier, a binder, an exeipient, and a dye.
17. The method of claim 12 wherein the huperzine A, vinpocetine, and acetyl -L-caritine together account for at least 90 wt% of a dosage unit of the supplement,
18. The method of claim 12 wherein the dosage unit of Lhe .supplement is equal or less than 1,600 mg.
19. The method of claim 12 wherein the cognitive function is a function of working memory, a function of long term memory consolidation, an aspect of mood, a function of fluid intelligence, spatial memory, and object working memory.
20. The method of claim 12 further comprising a stop of providing an interactive tool that allows at least one of validation of efficacy of the supplement and proper personal dosing of the supplement.
PCT/US2007/013376 2006-06-05 2007-06-06 Compositions and methods for enhancing brain function WO2008002382A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80394306P 2006-06-05 2006-06-05
US60/803,943 2006-06-05
US82020106P 2006-07-24 2006-07-24
US60/820,201 2006-07-24

Publications (2)

Publication Number Publication Date
WO2008002382A1 WO2008002382A1 (en) 2008-01-03
WO2008002382B1 true WO2008002382B1 (en) 2008-03-20

Family

ID=38832348

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/013316 WO2007145993A2 (en) 2006-06-05 2007-06-05 Modified compositions and methods for enhancing brain function
PCT/US2007/013376 WO2008002382A1 (en) 2006-06-05 2007-06-06 Compositions and methods for enhancing brain function

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013316 WO2007145993A2 (en) 2006-06-05 2007-06-05 Modified compositions and methods for enhancing brain function

Country Status (1)

Country Link
WO (2) WO2007145993A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010103539A2 (en) 2009-03-09 2010-09-16 Dinesh Shantilal Patel Sustained release oral formulation of vinpocetine
WO2011029176A1 (en) * 2009-09-14 2011-03-17 Michael Scott Buckley Concentration and mental performance amplifying formulation
AU2014235034A1 (en) * 2013-03-15 2015-10-01 Buck Institute For Research On Aging Improved cognitive supplements

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389623A1 (en) * 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
WO2004082609A2 (en) * 2003-03-14 2004-09-30 Pro-Health, Inc. Composition and method for appetite and carving suppression and mood enhancement
US20050053904A1 (en) * 2003-08-13 2005-03-10 Jennifer Shephard System and method for on-site cognitive efficacy assessment

Also Published As

Publication number Publication date
WO2007145993B1 (en) 2008-09-25
WO2007145993A2 (en) 2007-12-21
WO2008002382A1 (en) 2008-01-03
WO2007145993A3 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
Scheibler et al. Use of nystatin and chlorhexidine in oral medicine: Properties, indications and pitfalls with focus on geriatric patients
JP3672554B2 (en) Nutritional supplements for treating macular degeneration
EP1283054A4 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
US20060233892A1 (en) Topiramate compositions for treatment of headache
US5883086A (en) DHEA-containing nutritional supplement
US20120269868A1 (en) Compositions and methods for nutritional supplementation
CN101291650B (en) Anti-inflammatory compositions and methods of use
CN101287480A (en) Anti-inflammatory compositions and methods of use
KR20200095476A (en) Dietary composition containing a plant-based fatty acid source
WO2008002382B1 (en) Compositions and methods for enhancing brain function
JP3793764B2 (en) Nutritional supplement containing α-glucosidase inhibitor and α-amylase inhibitor
US6551628B1 (en) Herbal intestinal tract cleanser
TWI612905B (en) A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
US8197871B2 (en) Composition for headache treatment
US6979468B1 (en) Oral composition and method for the treatment of inflammatory cutaneous disorders
US20160361353A1 (en) Nitric oxide generator combined with pde5 inhibitors
US10391139B2 (en) Blood pressure reduction with dietary supplements
WO2002036127A2 (en) Methods and compositions for the treatment of polycystic ovary syndrome with chromium complexes
EP4157326A1 (en) Combination of active ingredients, compositions containing it and their use to sustain and strengthen the immune system
US20140271908A1 (en) Dietary supplements and methods for preventing and treating migraines
CH675684A5 (en)
US20110256237A1 (en) Methods and compositions for treating acne vulgaris and acne rosacea
US20230031548A1 (en) Composition for optimized dietary supplement formulations
WO2022230925A1 (en) Pyoderma ameliorating agent
CN104540509A (en) Pharmaceutical composition for liver regeneration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07795825

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07795825

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)